News

February 12, 2026

Affibody Medical announces outcome of rights issue

Stockholm, Sweden, February 12, 2026. Affibody Medical AB (publ) (”Affibody” or the “Company”) today announced the outcome of the Company’s rights issue of approximately SEK 307 million (the “Rights...

Read more

News

February 5, 2026

Report from Extraordinary General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, February 5, 2026. Affibody Medical AB (publ) today held an Extraordinary General Meeting. The following resolutions were adopted. The General Meeting resolved on the introduction of an...

Read more

News

January 19, 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend an extraordinary general meeting of the shareholders on Thursday...

Read more

News

November 26, 2025

Affibody’s Nomination Committee for the 2026 Annual General Meeting

Stockholm, Sweden, November 26, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2026 Annual General Meeting (AGM) to be held on May...

Read more

News

April 29, 2025

Positive Phase 2 Clinical Results for Izokibep in Psoriatic Arthritis Published

Solna, Sweden, April 29, 2025. Affibody AB (“Affibody”) today announced that a publication outlining the positive results from a Phase 2 clinical study with izokibep, a next generation IL-17...

Read more

News

February 2, 2025

Affibody regains worldwide rights to izokibep

Stockholm, Sweden, February 2, 2025. Affibody today announced that the company will regain all rights to izokibep. In 2021, Affibody and ACELYRIN, INC. entered into a license and collaboration...

Read more

News

January 15, 2025

Additional data from Affibody’s HER2 radiopharmaceutical program presented at PepTalk

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more

News

January 10, 2025

Affibody regains rights in selected Asian countries to izokibep

Stockholm, Sweden, January 10, 2025. Affibody today announced that the company has regained rights to izokibep in selected Asian countries. In 2020, Affibody and Inmagene Biopharmaceuticals entered into a...

Read more

News

January 7, 2025

Affibody’s Nomination Committee for the 2025 Annual General Meeting

Stockholm, Sweden, January 7, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2025 Annual General Meeting (AGM) to be held on May...

Read more